| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | 18.74% | Rosenblatt | → $98 | Reiterates | Buy → Buy |
| 08/04/2023 | 18.74% | Rosenblatt | $93 → $98 | Maintains | Buy |
| 07/28/2023 | 12.69% | Rosenblatt | → $93 | Reiterates | Buy → Buy |
| 06/01/2023 | 12.69% | Rosenblatt | → $93 | Reiterates | Buy → Buy |
| 04/26/2023 | 9.05% | Rosenblatt | → $90 | Reiterates | → Buy |
| 04/14/2023 | 40.55% | Tigress Financial | → $116 | Reiterates | → Buy |
| 02/03/2023 | 9.05% | Rosenblatt | $85 → $90 | Maintains | Buy |
| 11/18/2022 | — | Barrington Research | Downgrades | Outperform → Market Perform | |
| 11/07/2022 | 2.99% | Rosenblatt | $90 → $85 | Maintains | Buy |
| 10/14/2022 | 40.55% | Tigress Financial | $128 → $116 | Maintains | Buy |
| 05/24/2022 | 9.05% | Rosenblatt | → $90 | Initiates Coverage On | → Buy |
| 08/02/2021 | 39.34% | Barrington Research | → $115 | Upgrades | Market Perform → Outperform |
| 01/29/2021 | 7.84% | B. Riley Securities | $79 → $89 | Maintains | Neutral |
| 06/24/2020 | -12.76% | B. Riley Securities | $68 → $72 | Downgrades | Buy → Neutral |
| 05/05/2020 | -21.24% | JP Morgan | $66 → $65 | Maintains | Overweight |
| 05/05/2020 | -17.61% | B. Riley Securities | $71 → $68 | Maintains | Buy |
| 04/15/2020 | -13.97% | B. Riley Securities | $60 → $71 | Maintains | Buy |
| 03/24/2020 | -27.3% | B. Riley Securities | $57 → $60 | Upgrades | Neutral → Buy |
| 03/24/2020 | -27.3% | B. Riley Securities | → $60 | Upgrades | Neutral → Buy |
| 03/18/2020 | -30.93% | B. Riley Securities | $71 → $57 | Maintains | Neutral |
| 03/13/2020 | -20.03% | JP Morgan | → $66 | Upgrades | Neutral → Overweight |
| 01/10/2020 | -11.55% | B. Riley Securities | → $73 | Downgrades | Buy → Neutral |
| 08/02/2019 | -11.55% | B. Riley Securities | $67 → $73 | Maintains | Neutral |
What is the target price for Dolby Laboratories (DLB)?
The latest price target for Dolby Laboratories (NYSE: DLB) was reported by Rosenblatt on November 17, 2023. The analyst firm set a price target for $98.00 expecting DLB to rise to within 12 months (a possible 18.74% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dolby Laboratories (DLB)?
The latest analyst rating for Dolby Laboratories (NYSE: DLB) was provided by Rosenblatt, and Dolby Laboratories reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Dolby Laboratories (DLB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dolby Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dolby Laboratories was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
Is the Analyst Rating Dolby Laboratories (DLB) correct?
While ratings are subjective and will change, the latest Dolby Laboratories (DLB) rating was a reiterated with a price target of $0.00 to $98.00. The current price Dolby Laboratories (DLB) is trading at is $82.53, which is within the analyst's predicted range.